Phase Forward CFO Christopher Menard Selected for the Boston Business Journal’s “40 Under 40” Award

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that Christopher Menard, the company’s senior vice president and chief financial officer, has been named to the Boston Business Journal’s prestigious “40 Under 40” award list. The 12th annual award recognizes a broad spectrum of Boston’s best and brightest emerging business leaders under 40 years of age for their success in both career and community endeavors.

“Boston’s competitive advantage is its collective brainpower,” said Michael Olivieri, publisher of the Boston Business Journal. “Our ‘40 Under 40’ class reflects the deep talent pool that gives Boston its economic edge.”

To date at Phase Forward, Menard has been instrumental in the company’s successful execution of the IPO and secondary stock offering and the integration of four acquisitions. He also led the implementation of new global financial systems, and the negotiation of a 10-year lease and management of the build-out of the company’s new worldwide corporate headquarters.

“I’m honored to be included among this list of Boston-area professionals and entrepreneurs,” said Menard. “Phase Forward sits at the intersection of technology and life sciences, and we feel fortunate to have the opportunities we’ve had to collaborate with the state’s companies in both markets. It’s satisfying both professionally and personally to know that Phase Forward’s clinical trial and drug safety products will continue to play an important role not only in the success and betterment of our local community, but in communities around the globe.”

The October 2 issue of the Boston Business Journal will contain a special supplement which will profile the 40 honorees. Additionally, on Thursday, October 1 from 6:00-9:00 p.m., the publication will host an award reception at the Boston Park Plaza Hotel.

Just last month, Phase Forward was included in the FORTUNE Small Business 100 list for the second consecutive year, ranking 20th among America’s fastest growing small public companies. In June, Russell J. Campanello, the company’s senior vice president of human resources and administration, was honored with a Stevie® Award for Human Resources Executive of the Year. The company was also recognized earlier in the year by Frost & Sullivan with a 2009 Global Product Line Strategy Award.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024